Dongmei Ji

机构：Shanghai Medical College of Fudan University, Xuzhou Medical College, Anhui Medical University, Shanghai University of Electric Power, Fudan University, Fudan University Shanghai Cancer Center, The Fifth People's Hospital of Anyang, Second People’s Hospital of Huai’an, Shenyang Fifth People Hospital, First Affiliated Hospital of Anhui Medical University · ORCID：0000-0003-0647-0153

发表论文 279 篇 · 总被引 2211 次 · h-index 20

代表论文

• A Phase II study of SHR-A1921, a TROP2-targeted antibody–drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma (2026 · npj Precision Oncology · 被引 1)
• Multiparametric quantitative MRI combining SyMRI and MUSE-DWI for noninvasive stratification of HER2 status in breast cancer (2025 · Frontiers in Oncology · 被引 1)
• Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression (2026 · Journal of Clinical Oncology)
• Supplementary Table S8 from LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial (2026)
• Supplementary Figure S1 from LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial (2026)
• Supplementary Table S6 from LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial (2026)